IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Growth Catalyst
ImmunityBio (IBRX) shares slipped after an independent director filed to sell over 131,000 shares, valued at $1.2 million, which cooled retail sentiment despite the stock's recent gains. Investors are now focused on the potential FDA label expansion for Anktiva for papillary bladder cancer, with a decision expected in January 2027, and anticipated early Q2 sales updates. The company is also progressing with an AI-driven automated NK-cell manufacturing platform.
ImmunityBio (IBRX) Is Up 8.4% After Russell Index Removal Amid Anktiva Expansion Efforts - What's Changed
ImmunityBio (IBRX) saw an 8.4% stock increase despite being removed from several Russell value benchmarks. The company's investment narrative is largely tied to the expansion of its cancer drug Anktiva beyond its initial bladder cancer niche, with investors closely watching the FDA review for Anktiva's papillary bladder cancer label expansion and its Saudi Arabia launch. ImmunityBio is projecting significant revenue and earnings growth by 2029, suggesting a substantial upside to its current price, though some analysts remain cautious due to reliance on a single commercial asset and execution risks.
ImmunityBio (IBRX) Is Up 8.4% After Russell Index Removal Amid Anktiva Expansion Efforts - What's Changed
ImmunityBio's stock rose 8.4% despite its recent removal from Russell value benchmarks, as the company continues to expand the therapeutic uses and geographic reach of its cancer drug Anktiva. The core investment narrative for IBRX hinges on Anktiva's ability to broaden its indications beyond its initial bladder cancer niche and navigate the regulatory landscape, particularly with an FDA review for papillary bladder cancer expansion due in January 2027. While the Russell index changes affect ownership, the company's future success remains largely tied to clinical and regulatory outcomes for its single commercial asset.
IBRX - ImmunityBio Inc Revenue Breakdown
This page provides a detailed financial breakdown for ImmunityBio Inc. (IBRX), including its market capitalization, enterprise value, income, sales, key financial ratios, stock performance metrics, and ownership percentages. The data presented covers various aspects of the company's financial health and market activity.
ImmunityBio director Selecky sells $871k in stock
ImmunityBio director Christobel Selecky sold approximately $871,215 worth of common stock on June 29 and 30, 2026, through a pre-arranged trading plan. These sales followed the exercise of stock options to acquire shares at a lower price. Following these transactions, Selecky no longer directly holds shares in ImmunityBio.
ImmunityBio (IBRX) director pre-plans option exercises and sells 96,722 shares
ImmunityBio, Inc. director Christobel Selecky exercised stock options for 96,722 shares of Common Stock and subsequently sold all of them in pre-planned, open-market transactions on June 29-30, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on March 13, 2026, with shares sold at a weighted-average price of $9.0075. Following these transactions, Selecky reported no directly held Common Stock but still retains stock options.
IBRX (NASDAQ) insider exercise 1,000 shares; 95,722-share 10b5-1 sale
A Form 144 filing by ImmunityBio, Inc. (IBRX) disclosed an insider's recent stock activities. The filing detailed an exercise of 1,000 shares settled for cash on June 30, 2026, and a prior 10b5-1 sale by Christobel Selecky of 95,722 shares on June 29, 2026, for gross proceeds of $862,212.63. This is a notice of a proposed sale and past transactions rather than a confirmation of final settlement.
IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales
ImmunityBio, Inc. (IBRX) stock reached a three-month high as retail traders anticipate several July catalysts, including updates on Anktiva's expansion in Saudi Arabia, potential Q2 sales performance, and the company's global manufacturing efforts. The FDA's acceptance of an expansion filing for Anktiva's use in papillary bladder cancer in the U.S. and strong Q1 sales driven by Anktiva further fuel investors' bullish sentiment. The company is also making strides in automated NK-cell manufacturing, adding to the positive outlook.
IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales
ImmunityBio (IBRX) stock reached a three-month high as retail investors anticipate July catalysts, including potential updates on Anktiva's Saudi Arabian expansion for
[144] ImmunityBio, Inc. SEC Filing
ImmunityBio, Inc. (IBRX) filed a Form 144 with the SEC on June 29, 2026, indicating a proposed sale of 95,722 shares of common stock with an aggregate market value of $833,738.62. The shares were acquired through the exercise of stock options on the same date. The filing specifies Morgan Stanley Smith Barney LLC as the broker for the sale on NASDAQ.
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology
Sellas Life Sciences (SLS) and ImmunityBio, Inc. (IBRX) are drawing attention as the biotech sector approaches a strong monthly close, with analysts highlighting significant opportunities in immuno-oncology and other cancer treatments. Both companies are seeing their stocks perform well, driven by promising clinical trials for new cancer therapies and increased M&A buzz within the healthcare industry. The SPDR S&P Biotech ETF (XBI), which includes both SLS and IBRX, is experiencing one of its best monthly performances since December 2023.
Enterprise value to EBITDA forward of ImmunityBio, Inc. – NASDAQ:IBRX
This article provides a brief financial overview of ImmunityBio, Inc. (NASDAQ: IBRX), focusing on its enterprise value to EBITDA forward metric. It appears to be a stub or a section from a larger financial data platform, indicating key financial data for the company. The content primarily lists metadata and navigational elements typical of a stock market data page.
ImmunityBio director Simon Barry J. sells $196,907 of common stock
ImmunityBio director Simon Barry J. has sold 25,000 shares of the company's common stock for $196,907, with shares sold at an average price of $7.8763. This sale, executed under a Rule 10b5-1 trading plan, follows a significant price appreciation for the stock, though InvestingPro indicates it is currently overvalued. The company also recently announced FDA acceptance for a supplemental Biologics License Application for ANKTIVA and presented data from two Phase 3 trials.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume
ImmunityBio (NASDAQ:IBRX) saw its stock jump 11.8% on Friday, trading with significantly higher volume (41.2 million shares), which was 46% of its past five sessions' trading volume, potentially driven by the Russell reconstitution. Despite a director's planned sale of 25,000 shares, the focus is on whether the demand from the Russell inclusion will persist into the next trading week, especially as the company awaits a PDUFA deadline for its drug Anktiva in January 2027.
Enterprise value to EBIT forward of ImmunityBio, Inc. – NASDAQ:IBRX
This article focuses on the "Enterprise value to EBIT forward" metric for ImmunityBio, Inc. (NASDAQ: IBRX). It appears to be an entry from a financial data platform, providing a snapshot of this specific financial ratio for the company. The content itself seems to be a page from TradingView, detailing various financial and community features, but the core information presented is the mentioned financial metric for IBRX.
Form 4 Immunitybio Inc For: 26 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Immunitybio Inc. dated June 26. It indicates the latest filing for the company. The article also provides IBRX's stock performance.
Form 4 Immunitybio Inc For: 26 June By Investing.com
This article reports on a Form 4 filing for Immunitybio Inc on June 26th. It notes that the company's stock symbol is IBRX and includes its current price performance. The content primarily consists of market data and unrelated financial news headlines from Investing.com.
ImmunityBio (NASDAQ: IBRX) director sells 25,000 shares under 10b5-1 plan
ImmunityBio (NASDAQ: IBRX) director Barry J. Simon sold 25,000 shares of common stock on June 24, 2026, at a weighted average price of $7.8763 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025. Following the sale, Simon still directly holds 2,802,788 shares of ImmunityBio common stock.
Price to sales forward of ImmunityBio Inc – SWB:26CA
This article provides financial information for ImmunityBio Inc, traded on the Stuttgart Stock Exchange under the symbol SWB:26CA. It specifically focuses on the company's forward price to sales ratio. The content is presented by TradingView, sourcing market data from ICE Data Services and reference data from FactSet.
Price to sales forward of ImmunityBio, Inc. – NASDAQ:IBRX
This article provides financial data for ImmunityBio, Inc. (NASDAQ: IBRX), specifically focusing on its forward price-to-sales ratio. It indicates that the current market for this stock is closed and shows no active trades. The page is part of a larger trading platform, offering various tools and community features.
ImmunityBio (NASDAQ:IBRX) rises as Russell index rebalancing and high multiple draw buyers
ImmunityBio (NASDAQ:IBRX) shares rose 9.2% on June 26, 2026, driven by anticipation of the Russell index rebalancing, as its market capitalization surpassed the threshold for inclusion in the Russell 1000. Traders piled into the biotech company, which is already up more than four times this year, pushing its market value to $8.74 billion, significantly above FTSE Russell's $5.7 billion cutoff. Despite a high valuation relative to product revenue and a recent FDA warning letter, strong demand for its drug ANKTIVA and a robust cash position were noted by company executives.
Is Speculation About a Russell 1000 Shift Quietly Rewriting ImmunityBio’s (IBRX) Investment Narrative?
ImmunityBio (IBRX) is attracting retail speculation about a potential shift from the Russell 2000 to the Russell 1000 index, which could impact liquidity, volatility, and passive ownership. While this index move doesn't alter the core clinical, regulatory, and funding milestones, financing risk remains a significant concern for investors due to the company's large losses and tight cash runway. Fair value estimates for ImmunityBio vary widely among analysts, underscoring the divergence in views regarding the company's future prospects.
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast
24/7 Wall St. rates Immunitybio Inc (IBRX) as a "BUY" with a 12-month target price of $16.16, representing a 107.17% upside from its current price of $7.80. The forecast includes an optimistic scenario of $17.72 and a conservative scenario of $11.84, backed by 100% "Buy" ratings from three Wall Street analysts. Long-term projections for 2030 suggest an average price of $38.43, with a potential range between $28.82 and $48.03.
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast
24/7 Wall St. rates Immunitybio Inc (IBRX) as a "BUY" with a 12-month target price of $16.16, suggesting a 107.17% upside from its current price of $7.80. The forecast includes optimistic and conservative scenarios of $17.72 and $11.84, respectively, supported by 3 Wall Street analyst "Buy" ratings. Long-term projections extend to 2031, with an average price target of $57.25, highlighting potential significant returns.
Price to book forward of ImmunityBio, Inc. – NASDAQ:IBRX
This article provides a financial data point for ImmunityBio, Inc. (NASDAQ: IBRX), specifically its forward price-to-book ratio. The content appears to be a stub or a data entry page, indicating where this financial metric can be viewed within the TradingView platform.
ImmunityBio (IBRX) Valuation In Focus After Russell 1000 Talk Lifts Interest
ImmunityBio (IBRX) is gaining attention due to speculation about its potential move from the Russell 2000 to the Russell 1000 index, causing a 1% after-hours stock move. The company shows strong long-term share price momentum despite recent dips, and analysts value it at a significant discount, with a fair value estimate of $13.50 against its last close of $7.32. This valuation is supported by the global expansion of its product ANKTIVA, but reliance on this product and regulatory risks pose pressure points.
Anktiva Vs Keytruda: ImmunityBio Exec Chair Slams FDA For Double Standards In Approvals
ImmunityBio's Executive Chairman, Patrick Soon-Shiong, has criticized the FDA for what he perceives as a double standard in drug approvals, specifically comparing Anktiva to Merck’s Keytruda. Soon-Shiong argues that the FDA requires Anktiva to undergo extensive randomized trials for each cancer type, while Keytruda was approved and expanded based on single-arm trials. He claims this regulatory disparity is preventing over 13,000 patients from accessing potentially life-saving treatment with Anktiva outside its current bladder cancer indication.
ImmunityBio, Inc. (NASDAQ:IBRX): Are Analysts Optimistic?
This article analyzes the current sentiment among analysts regarding ImmunityBio, Inc. (NASDAQ:IBRX). It will explore whether the current consensus leans towards an optimistic outlook for the company's future performance. The piece likely delves into financial metrics, recent developments, and expert opinions to gauge this sentiment.
How ASCO Phase 3 ANKTIVA Data At ImmunityBio (IBRX) Has Changed Its Investment Story
ImmunityBio's ANKTIVA immunotherapy showed promising Phase 3 data at the ASCO Annual Meeting for advanced non-small cell lung cancer and bladder cancer, reinforcing its investment thesis of becoming a broad immunotherapy platform. With an FDA sBLA review for bladder cancer anticipated by January 2027, the company faces both significant growth projections—$1.2 billion revenue by 2029—and risks due to high cash burn and single-franchise concentration. Investors are encouraged to review comprehensive analyses of the company's financial health and potential risks alongside these positive clinical trial outcomes.
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ImmunityBio, Inc. (IMMP) for corporate wrongdoing. The firm encourages investors who purchased ImmunityBio securities before January 19, 2026, and still hold them, to contact them to assist with the investigation. The representation of investors in class actions is on a contingency fee basis.
ImmunityBio (IBRX) director Wesley Clark receives 65,600 stock options at $7.25 strike
ImmunityBio (IBRX) director Wesley Clark has been granted 65,600 stock options with an exercise price of $7.25 per share, expiring on June 9, 2036. These options will vest 100% on the earlier of June 9, 2027, or the date immediately before the next annual stockholder meeting, contingent on his continued service. This transaction is an award, not an open-market purchase, and is part of the company’s 2025 Equity Incentive Plan.
ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026
ImmunityBio, Inc. (NASDAQ: IBRX) is highlighted as one of 2026's best-performing growth stocks, following its presentations at the ASCO Annual Meeting. The company showcased research on its FDA-approved immunotherapy ANKTIVA, designed to activate immune cells against various solid tumors, indicating its potential in cancer care. ImmunityBio focuses on developing next-generation immunotherapies for cancer and infectious diseases.
ImmunityBio (IBRX) director receives 65,600 stock options at $7.25 strike
ImmunityBio director Wendel Bruce was granted 65,600 stock options with an exercise price of $7.25 per share. These options are part of his compensation, vest fully on the earlier of June 9, 2027, or before the next annual stockholder meeting, and expire on June 9, 2036. This transaction is a grant and not an open-market purchase or sale of shares.
Director at ImmunityBio (NASDAQ: IBRX) awarded 65,600 options
ImmunityBio director Michael D. Blaszyk was granted 65,600 stock options with an exercise price of $7.25 per share, expiring on June 9, 2036. The options will fully vest on the earlier of June 9, 2027, or the date just before the next annual stockholder meeting, contingent on his continued service. This transaction is a compensation-related grant rather than a market purchase.
A Look At ImmunityBio (IBRX) Valuation After FDA Review Of ANKTIVA And BCG Combination
ImmunityBio (IBRX) is under investor scrutiny after the FDA accepted its supplemental Biologics License Application for ANKTIVA plus BCG for bladder cancer, with potential for expanded use and cost savings. Despite recent share price volatility, including a 258.91% year-to-date return, the company is considered undervalued with a fair value estimate of $13.50, significantly higher than its current price of $7.25. This valuation is largely driven by expectations of rapid global expansion of ANKTIVA, rising margins, and increased earnings multiples.
ImmunityBio (IBRX) director awarded 65,600 stock options at $7.25 strike
ImmunityBio director Linda Maxwell was granted 65,600 stock options with an exercise price of $7.25 per share, expiring on June 9, 2036. The options will vest 100% on the earlier of June 9, 2027, or the date before the next annual stockholders' meeting, provided she continues as a "Service Provider." This transaction, reported on Form 4, is a compensation grant, not an open-market purchase.
FDA to Review Expanded Use of Cancer Drug
ImmunityBio Inc. has received good news concerning its Anktiva drug, which treats forms of bladder cancer. The FDA has accepted a review application for expanded use of Anktiva, with a decision due by January 6, next year. Additionally, ImmunityBio acquired a strain of the Bacillus Calmette-Guerin (BCG) treatment from Japan BCG Laboratory, giving it exclusive U.S. rights to this critical component used alongside Anktiva.
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ImmunityBio, Inc. (NASDAQ: IBRX) securities. The firm encourages investors who bought securities before January 19, 2026, and still hold them, to contact them to learn more about the investigation into potential corporate wrongdoing by ImmunityBio and its officers or directors. The firm operates on a contingency fee basis, meaning ImmunityBio investors incur no direct cost.
ETFs Investing in ImmunityBio Inc Stocks
This article lists various ETFs that hold ImmunityBio Inc (26CA) stocks, providing financial data for each fund. The data includes market value, weight of ImmunityBio Inc in the ETF, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The ETFs listed cover a range of investment strategies, from passive biotech and small-cap funds to active total market and specialized theme funds.
ImmunityBio Inc Cash Flow – XETR:26CA
This article provides details on ImmunityBio Inc.'s cash flow activities, specifically for the XETR:26CA stock. It highlights that the free cash flow for Q1 2026 was -66.77 million EUR, and for the full year 2025, it was -262.90 million EUR with operating cash flow at -259.63 million EUR. The data includes an overview of operating, investing, and financing activities, along with historical cash flow statements from 2013 to 2025.
Director Barry Simon Sells 23,033 Shares of ImmunityBio Inc (IBRX)
ImmunityBio Inc Director Barry Simon sold 23,033 shares of the company on June 4, 2026, reducing his total holdings to 2,827,788 shares. This sale is part of a pattern over the past year where Simon has sold 425,000 shares with no insider purchases. ImmunityBio, a clinical-stage biotechnology company, is currently trading at $7.18, significantly below its GF Value of $41.98, leading GuruFocus to classify it as a "Possible Value Trap, Think Twice."
ImmunityBio (IBRX) director Simon sells 23,033 shares under Rule 10b5-1 plan
ImmunityBio director Barry J. Simon sold 23,033 shares of Common Stock at a weighted average price of $7.1769 per share on June 4, 2026. This open-market sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025. Following the transaction, Simon directly holds 2,827,788 shares, indicating this was a routine portfolio management activity.
ImmunityBio (IBRX) Is Down 5.6% After New Phase 3 ANKTIVA Lung Cancer Data Release – Has The Bull Case Changed?
ImmunityBio (IBRX) saw its stock drop 5.6% following the release of new Phase 3 data for its ANKTIVA drug in advanced non-small cell lung cancer at the 2026 ASCO Annual Meeting. This data, alongside continued development in bladder cancer, is crucial for ImmunityBio's investment narrative, as the company needs to expand ANKTIVA's application beyond its initial approval to achieve significant revenue growth and profitability. The article highlights that analysts project substantial revenue and earnings growth for ImmunityBio by 2029, with a fair value indicating a significant upside, provided the company can successfully diversify its product offerings and manage its financial constraints.
IBRX: ANKTIVA delivers durable cancer responses, drives global growth, and expands into new indications
The article highlights ImmunityBio, Inc.'s ANKTIVA, discussing its strong clinical and commercial progress. ANKTIVA has shown efficacy and durability in treating bladder and lung cancer, leading to expanding global approvals. The company also maintains solid financials and is developing new BCG strains to address shortages.
[144] ImmunityBio, Inc. SEC Filing
This article details an SEC Form 144 filing by ImmunityBio, Inc. (IBRX) on June 4, 2026, primarily concerning the proposed sale of securities. The filing indicates a significant number of shares (268,033) with an aggregate market value of over $2.9 million intended for sale, acquired through "various methods & dates" from the issuer since 2013. The company also recently announced positive clinical trial data and FDA acceptance for one of its therapies.
ImmunityBio stock rises after FDA compliance response
ImmunityBio shares rose 3% after the company submitted a comprehensive response to the FDA regarding promotional compliance issues, specifically concerning a television advertisement and a podcast. The biotech firm confirmed the ad was never broadcast and removed the podcast, also implementing enhanced advertising compliance measures and executive training. The company emphasized its commitment to distinguishing between investigational pipeline aspirations and approved therapy indications.
Assessing ImmunityBio (IBRX) Valuation After Strong Multi Year Returns And ANKTIVA Expansion
ImmunityBio (IBRX) is attracting investor attention due to its recent stock performance, including a year-to-date return of 258.42% and a 1-year return of 171.16%, despite a recent dip. The stock is currently trading at US$7.24, significantly below its analyst price target of US$13.00, suggesting it is undervalued, with its most followed narrative pegging fair value at $13.50 per share. This potential undervaluation is further supported by the global expansion of its core therapy, ANKTIVA, into 33 countries, which is expected to drive substantial future revenue growth.
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
ImmunityBio, Inc. announced the presentation of new clinical and comparative data for its ANKTIVA® immunotherapy at the American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations highlight ANKTIVA-based approaches in advanced non-small cell lung cancer (NSCLC) and Bacillus Calmette–Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC). The data, including findings from two Phase 3 trials and a matched adjusted indirect comparison, underscore ANKTIVA's role in activating immune cells to potentially restore immune function and enhance responses to checkpoint inhibitors.
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
ImmunityBio, Inc. announced presentations at the ASCO 2026 Annual Meeting, showcasing new clinical and comparative data for its IL-15 receptor agonist immunotherapy, ANKTIVA®, in lung and bladder cancer. The presentations include results from two randomized Phase 3 trials in advanced non-small cell lung cancer (NSCLC) and a matched adjusted indirect comparison in BCG unresponsive non-muscle invasive bladder cancer (NMIBC). The company emphasizes ANKTIVA's role in activating critical immune cells to restore immune function and potentially improving outcomes for cancer patients.
How FDA Review of ANKTIVA Bladder Cancer sBLA Could Impact ImmunityBio (IBRX) Investors
ImmunityBio's ANKTIVA has an expanded FDA review for bladder cancer, focusing on how existing data for CIS can be applied to papillary-only disease. The outcome of this sBLA review is a critical near-term catalyst for ImmunityBio, as it will influence the company's revenue projections and investment narrative, especially given prior regulatory scrutiny and the current cash constraints. Investors are closely watching the FDA's stance on extrapolating single-arm data, which could affect future label expansions and the drug's revenue generation.
